^
Association details:
Biomarker:NF1 mutation
Cancer:Sarcoma
Drug:vociprotafib (RMC-4630) (PTPN11 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Source:
Title:

LB001 - Anti-tumor activity and tolerability of the SHP2 inhibitor RMC-4630 as a single agent in patients with RAS-addicted solid cancers

Published date:
04/09/2021
Excerpt:
...initial data from a phase 1 trial of RMC-4630 showed anti-tumor activity in tumors harboring diverse mutations in the RAS pathway including KRASG12C, KRASG12D, NF1LOF, and BRAF Class 3....Of the 80 efficacy evaluable patients, there was 1 CR (NF1LOF uterine carcinosarcoma), 1 PR (KRASG12C NSCLC), and 1 unconfirmed PR (KRASG12D NSCLC). Tumor regressions were observed in another 11 patients (-2.4% to -27.1%).